U.S. britain, Germany, the new pneumonia vaccine will be far away?

The outbreak of new pneumonia is still escalating, and the development of vaccines has become a natural priority. As of February 3, 2020, 20438 cases of new pneumonia had been confirmed nationwide, 425 deaths had been reported, 632 cases had been cured and 23,214 were suspected. Overseas, the pneumonia epidemic can be said to have become a global epidemic, its impact can not be underestimated – according to Tencent News real-time data, as of the time of writing, overseas countries have been confirmed 160 cases, 1 death.

U.S. britain, Germany, the new pneumonia vaccine will be far away?

Anthoy Fauci, director of the National Institute of Allergy and Infectious Diseases, says:

The new coronavirus is so contagious that it will almost certainly become a global epidemic, one that continues to spread on two or more continents.

Based on this, all forces have also begun to step up the development of vaccines, with a view to early control of the spread of the epidemic.

Increased investment by governments

Of course, in the face of the global escalation of the new pneumonia epidemic, governments in the introduction of travel ban, further strengthen restrictions on Chinese travelers, but also pay attention to the outbreak, hoping to speed up the development of new coronavirus vaccine:

The U.S. government said last week it was accelerating research and development of a coronavirus vaccine with a view to starting the first phase of trials within three months.

Anja Karliczek, Germany’s research minister, said on January 31st that a coronavirus vaccine was expected to be developed within a few months.

On February 3rd, local time, the British government announced that it would invest 20 million pounds ($26 million) to accelerate the development and production of a new coronavirus pneumonia vaccine. The vaccine development will be led by CEPI (Global Alliance for Innovation in Epidemic Prevention).

On the same day, Matt Hancock, the UK health secretary, announced the latest investment plan during a visit to the Burton Down laboratory in the UK.

Vaccines are our best way to fight many deadly diseases, including coronaviruses.

Founded in 2017, CEPI is a global cooperative for the prevention and fight of epidemics, supported by public institutions, private and charitable organizations, with institutes in London, London, Oslo, Norway, and Washington, D.C. CEPI announced on January 31st that it has been established in 2000 with the german-based biotech company CureVac, a German-based company focused on the development of RNA pharmaceuticals, and is a leader in RNA pharmaceuticals. Cooperation is established to develop a coronavirus vaccine.

Richard Hatchett, CEPI’s chief executive, said the UK government’s investment was “at a critical time for the global race to respond to the new coronavirus”, saying:

The rapid spread and unique epidemiological characteristics of this new coronavirus around the world are worrying, and we hope to complete clinical trials of the vaccine within 4 months with our partners.

In response to this commitment, he said the earliest clinical trials would test the safety of the vaccine, which would take about 2-4 months. Richard Hatchett, meanwhile, agrees that this is an easy goal and that there is no guarantee of success at this time, but there are bound to be many challenges in the coming months.

All over the laboratory fire power

At the same time, biotechnology companies and vaccine laboratories around the world are also in full swing:

Moderna, a Massachusetts-based biotech company, is developing a vaccine designed by researchers at the National Institutes of Health (NIH) and is expected to undergo clinical trials by April 2020;

Inovio, a Philadelphia-based biotech company, is preparing for laboratory and animal trials of the vaccine it has developed. It is understood that this work has received $9 million from the Alliance for Innovation in Epidemic Prevention;

Johnson and Johnson, the pharmaceutical industry leader, is also working on a vaccine, but it will take a year for the vaccine to hit the market.

As far as the methodology is concerned, most laboratories are referring to the experience of vaccine development for SARS (Severe Acute Respiratory Syndrome) and MERS (MerS) coronavirus. Florian Krammer, a professor of vaccines at the Icahn School of Medicine at Mount Sinai in New York City, says:

Based on these vaccines, we can immediately develop a vaccine model for the new coronavirus. Our lab is doing research, and there are about 50 labs in the United States.

Keith Chappell, a virologist at the University of Queensland in Australia, recently told National Public Radio that his lab is rapidly studying the vaccine using the genetic sequence of the new coronavirus, which chinese researchers have in fact cracked and shared with the world:

Our goal is to manufacture safe and effective medicines with sequence information over 4 months.

Successful cure, emerging Sugon

At present, there are already curable cases in overseas countries, while Thailand has an alarming rate of cures compared to other overseas countries.

On the afternoon of February 2, Thai Deputy Prime Minister and Minister of Health Anutin held a press conference, said that Thai medical personnel found an effective treatment of the new coronary virus infection pneumonia drug formula, patients after 48 hours of treatment, the test results were negative.

At the press conference, Dr. Kriangsak Atipornwanich, an expert physician at Rajavithi Hospital in Bangkok, said that the medical team treated a patient in his 70s with an anti-flu virus drug combined with anti-AIDS drugs, which worked well and improved symptoms after 12 hours of medication. The test results were negative after 48 hours. It is reported that both drugs are the Thai government medical organizations produced standard drugs.

Meanwhile, the United States has recently successfully cured a new type of pneumonia patient.

U.S. britain, Germany, the new pneumonia vaccine will be far away?

In the early hours of February 1, 2020, Beijing time, the New England Journal of Medicine (NEJM) reported in a short report on the first successful cure in the United States of a confirmed new type of coronavirus pneumonia. According to the article, the 2019-nCoV infection (new coronavirus) infection in the United States after isolation treatment, the use of the antiviral drug Remdesivir (Redsivir) immediately after the effect.

The above-mentioned drug Remdesivir is an experimental anti-Ebola virus drug developed by Gilead, the world’s number one antiviral drug research company and one of the largest biotechnology companies in the United States, to suppress RNA syntraenzyme (RdRp), which is present in the 2019-nCoV virus. At present, Remdesivir has not been approved in the United States, in line with the principle of “sympathetic medication”, by doctors used in the first confirmed patient treatment, did not expect significant results.

Successful lying patients is like seeing Sugon in this bone-eye. However, drugs that may be effective at the moment will still take some time from clinical trials to approval, production and marketing.

And time race.

Everyone knows that this battle will win, and it is unknown when it will be won.

Amesh Adalja, senior scholar at The Center for Health and Safety at Johns Hopkins University, said:

Although we may conduct clinical trials within a year, I do not expect the coronavirus vaccine to be available within a year.

In fact, getting millions of doses of the new coronavirus vaccine into the hands of doctors and patients is even more complicated than the development process itself.

As Florian Krammer says:

We can actually develop a vaccine in two weeks, but that doesn’t make much sense for the current situation, because any new vaccine will face production and regulatory hurdles that will take at least a few months to overcome. In addition, there is no vaccine for any coronavirus on the market, not even for SARS or MERS. If it’s just flu, it may be easier to start because the technology for mass production of influenza vaccines is in place. There is no ready-made manufacturing technology for the coronavirus vaccine, which is the crux of the problem. And vaccine developers must prove safety and efficacy to federal regulators, not to mention subsequent production and mass marketing.